Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Change in Receivables (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Change in Receivables for 4 consecutive years, with -$31000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables fell 188.57% to -$31000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$78000.0, a 368.97% decrease, with the full-year FY2024 number at -$22000.0, down 833.33% from a year prior.
  • Change in Receivables was -$31000.0 for Q3 2025 at Orchestra BioMed Holdings, down from -$6000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $95000.0 in Q2 2023 to a low of -$85000.0 in Q3 2023.
  • A 4-year average of -$6000.0 and a median of -$4500.0 in 2025 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 9400.0% in 2023; the steepest drop was 631.25% in 2023.
  • Orchestra BioMed Holdings' Change in Receivables stood at $16000.0 in 2022, then fell by 18.75% to $13000.0 in 2023, then tumbled by 392.31% to -$38000.0 in 2024, then grew by 18.42% to -$31000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Change in Receivables are -$31000.0 (Q3 2025), -$6000.0 (Q2 2025), and -$3000.0 (Q1 2025).